Chagas disease, considered a neglected disease, is a parasitic infection caused by Trypanosoma cruzi, which is endemic throughout the world. Previously, the antimicrobial effect of Mastoparan (MP) from Polybia paulista wasp venom against bacteria was described. To continue the study, we report in this short communication the antimicrobial effect of MP against Trypanosoma cruzi. MP inhibits all T. cruzi developmental forms through the inhibition of TcGAPDH suggested by the molecular docking. In conclusion, we suggest there is an antimicrobial effect also on T. cruzi.
Chagas disease, caused by the Trypanosoma cruzi parasite, is endemic worldwide (WHO, 2010) and considered a neglected disease (WHO, 2012; Rassi et al., 2012) . However, according to the World Health Organization (WHO), approximately 7.7e10 million individuals are infected.
Nifurtimox and benznidazole, drugs used to treat Chagas' disease, are ineffective in the chronic phase of the disease and have marked side effects (Cançado, 2002; Coura, 2007; Coura and Borges-Pereira, 2011; Araujo-Jorge, 2014) . Therefore, there is an urgent need for new, safe and effective drugs.
The vital dependence on glycolysis as energy source makes the glycolytic enzymes of T. cruzi attractive targets for drug design. The inhibition of glyceraldehyde-3-phosphate dehydrogenase from T. cruzi (TcGAPDH), important for the parasite's life cycle, has been identified as a molecular target to new drugs (Harris and Waters, 1976; Nowicki et al., 2008; Soares et al., 2013; Prokopczyk et al., 2014; Zinsser et al., 2014) .
Several studies have sought to discover novel antiparasitic substances from animal venoms (Passero et al., 2007; Adade et al., 2011 Adade et al., , 2013 2014; Lima et al., 2016) . The trypanocidal activity of Hymenoptera venoms and their compounds has been demonstrated (Adade et al., 2012 (Adade et al., , 2013 Lima et al., 2016) . Wasp venom cationic peptides, namely mastoparan and its analogs, have shown very important potency as future antimicrobial agents (Dongol et al., 2016) . The action of mastoparan from Polybia paulista wasp venom against bacteria (dos Santos Cabrera et al., 2008; Souza et al., 2009 Souza et al., , 2011 has been previously demonstrated. To continue the study of the antimicrobial effect of mastoparan (MP) from Polybia paulista venom, we report in this short communication its action on Trypanosoma cruzi and performed molecular docking of MP in the active site of TcGAPDH as a molecular target.
Materials and methods

Mastoparan peptide (MP) and T. cruzi strain
The mastoparan peptide (MP) isolated from Polybia paulista wasp venom with the primary sequence IDWLKLGKMVMDVL (Souza et al., 2004) was kindly provided by Dr. Mario Palma (Universidade de São Carlos, São Paulo, Brazil) . For the experimental assays, final concentrations of 120, 60, 30, 15, 7.5, 3 .75 and 1.87 mM were utilized, with sterile PBS being used as negative control (pH 7.4). Trypanosoma cruzi Y strain was isolated in São Paulo University Parasites Biochemical Laboratory and donated in epimastigote and trypomastigote forms.
Effect of MP on epimastigote forms of T. cruzi
Epimastigote forms of T. cruzi Y strain were plated in Liver Infusion Tryptose medium supplemented with antibiotics and 10% of FBS with different concentrations of MP and Benznidazole (Bz), incubated at 28 C for 24, 48 and 72 h. Parasite growth inhibition was quantified in a Neubauer chamber (Abe et al., 2002; Gonçalves et al., 2002) .
Effect of MP on trypomastigote forms of T. cruzi
The trypomastigote forms of T. cruzi obtained by infecting LLCMK2 cells, were incubated at 37 C in an atmosphere with 5% CO 2 in DMEM medium (Vitrocell, São Paulo, Brazil) supplemented with antibiotics and 2% of FBS (Aparicio et al., 2004) . Cells were incubated with different concentrations of MP and Bz for 24 h. Parasite growth inhibition was quantified in a Neubauer chamber (Abe et al., 2002; Gonçalves et al., 2002) .
Effect of MP on amastigote forms of T. cruzi
LLC-MK2 cells were seeded in 24-well plates containing glass coverslips (13-mm diameter) cultivated in DMEM supplemented with 10% FCS, and maintained at 37 C in a 5% CO 2 atmosphere for 24 h. Cells were infected with trypomastigote forms (parasite: host cell ratio of 20:1) in DMEM medium containing 2% FCS. After 48 h of infection, the non-internalized parasites were removed and the cells were cultivated in 2% FCS DMEM medium with or without MP (IC50 of trypomastigotes: 10.62 mM) and Bz (IC50 of trypomastigotes: 282 mM). The coverslips were collected in after 48 h, washed with PBS, fixed in Bouin solution and stained with Giemsa (Adade et al., 2011; Lima et al., 2016) . The percentage of infected cells and the number of intracellular amastigotes per 100 cells was determined by counting 300 cells in triplicate. The LLC-MK2 cells were donated by São Paulo University Parasites Biochemical Laboratory.
Flow cytometry analysis to assess parasite death
Epimastigote forms treated with MP (60 mM) incubated for 24 h were stained with FITC-conjugated to annexinV/7AAD according to the manufacturer's instructions (BD Pharmigen, California, USA). The population of AX-7AAD viable cells was evaluated. Mitochondrial transmembrane potential, Reactive oxygen species (ROS) were also performed. Epimastigote forms were treated with MP (60 mM) for 24 h and stained with Rhodamine 123 (10 mg/mL), DCFH-DA (20 mMol/L) for 6 h according to the manufacturer's instructions (SigmaeAldrich™, St. Louis, USA). The results were established by determining the fold change (treated/non-treated cell ratio) of the geometric mean of fluorescence. At the end of each incubation period, the cells were washed and submitted to flow cytometry analysis. All data were collected in a FACSCalibur system and analyzed using the Cell Quest software (Becton-Dickinson, California, USA).
Molecular docking
We obtained the MP peptide three-dimensional structure starting from the primary sequence IDWLKLGKMVMDVL (Souza et al., 2004) in Avogadro 1.1.1 program (Hanwell et al., 2012) . The geometric optimization of the MP structure was performed using semiempirical Hamiltonian PM7 in MOPAC2012 program (http:// openmopac.net). The crystallographic structure of the TcGAPDHchalepin complex was obtained from RCSB Protein Data Bank (PDB code: 1K3T) elucidated by Pavão et al. (2002) . To identify potential binding sites, molecular docking was carried out employing automated docking in a ZDOCK server (http://zdock.umassmed.edu/) with the ZDOCK 3.0.2 program (Pierce et al., 2014; Mintseris et al., 2007) . The ligand used was the optimized MP peptide, and the target was the TcGAPDH enzyme after the removal of the chalepin of the TcGAPDHechalepin complex. The best MP pose was selected based on the best-ranked conformation of the peptide in the enzyme, and used for the construction of TcGAPDH-MP complex. The TcGAPDH-chalepin complex was used to compare the position of the ligand in the binding site. Molecular graphics were performed using the UCSF Chimera 1.8 package (Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco) (Pettersen et al., 2004) .
Statistical analysis
The statistical analysis was performed using the GraphPad Prism 5 program (GraphPad Software, San Diego, CA, USA). IC50 values were determined by nonlinear regression. Data were analyzed using one-way analysis of variance (ANOVA) followed by Dunnett's post-test. Significance was defined as *p < 0.05.
Results and discussion
In the present study, the treatment of epimastigotes with MP resulted in dose-dependent growth inhibition, with an IC50/24 h treatment of 61.4 ± 4 mM, IC50/48 h of 32.5 ± 4 mM and IC50/72 h of 35.24 ± 6 mM, while BZ showed IC50/24 h treatment of 218 ± 15 mM, IC50/48 h of 61.1 ± 3 mM and IC50/72 h of 16.5 ± 1 mM for the Y strain of T. cruzi. The treatment of trypomastigote forms with MP also resulted in dose-dependent growth inhibition, with an IC50 of 5.31 ± 1 mM and IC50 of BZ of 282 ± 20 mM for the Y strain of T. cruzi.
In the amastigote assay, untreated infected cells exhibited a higher infection profile compared to MP-treated cells, with reduced numbers of amastigotes per 100 cells at 48 h of incubation, as well Bz (Fig. 1A) .
It has been previously demonstrated that antimicrobial peptides show a high level of toxicity against both Gram-positive and Gramnegative bacteria, as well as fungi, viruses, metazoan parasites and even cancer cells (Zasloff, 2002; Hoskin and Ramamoorthy, 2008) .
Antibacterial (dos Santos Cabrera et al., 2008; Souza et al., 2009 Souza et al., , 2011 , antifungal (Wang et al., 2014) and anticancer (De Azevedo et al., 2015) effects of mastoparans have been described. Recently, the antiparasitic effect of mastoparans and their analogues has been described against Plasmodium falciparum (Carter et al., 2013; Peatey et al., 2013) . In this study, we demonstrated the trypanocidal effect of the MP on the all developmental forms of T. cruzi Y strain. Corroborating our findings, other authors have shown the trypanocidal effect of Hymenoptera venoms (Adade et al., 2012; Lima et al., 2016) , as well as of its antimicrobial peptides (Adade et al., 2013) .
To evaluate the action mechanism, cytometry flow was also performed on a proliferative form, the epimastigote. Necrosis and apoptosis could be evaluated with staining of 7AAD/AX, overproduction of ROS and alterations on transmembrane mitochondrial potential (Vanden Berghe et al., 2013) . Our findings did not show any increase of marked cells on 7AAD/AX (Fig. 1B) , but showed increase on ROS (Fig. 1C) and reduction of transmembrane mitochondrial potential (Fig. 1D) . So we investigated the interaction between MP and TcGAPDH, since this enzyme is crucial to T. cruzi survival and it is responsible for many biological processes, including cell death regulation.
GAPDH is a simple, highly conserved enzyme required for glycolysis, the process of turning glucose into energy. Over the past 20 years, however, scientists have been uncovering additional roles of GAPDH, such as oxidative stress response, maintenance of DNA integrity, apoptosis, autophagy, histone gene regulation (Sirover, 2011) .
The great dependence of trypanosomatids on glycolysis to obtain energy makes glycolytic enzymes attractive targets for drug design against Chagas' disease. T. cruzi glyceraldehyde-3-phosphate dehydrogenase (TcGAPDH) which catalyzes the oxidative phosphorylation of D-glyceraldehyde-3-phosphate (G3P) into 1,3-bisphosphoglycerate (1,3-BPG) coupled to reduction of nicotinamide adenine dinucleotide (NADþ) to NADH, is a key enzyme in the glycolytic pathway (Cheleski et al., 2010) .
Recently, Prokopczyk et al. (2014) , Soares et al. (2013) and Maluf et al. (2013) have investigated TcGAPDH as a target for drug design. We used molecular docking analysis to suggest a mechanism of action of the peptide on the parasite through the study of the interaction between TcGAPDH and the MP. The MP best-ranked pose in the docking simulation is shown in Fig. 2A , together with the chalepin pose, a known inhibitor of TcGAPDH (obtained from crystallographic data of the TcGAPDHechalepin complex) for comparison (Pavão et al., 2002) . We can observe that the docking pose of MP peptide is similar to that occupied by the chalepin molecule in the TcGAPDH active site.
The region of the nearest neighbors between MP peptide and the atoms of amino acid residues of the binding site is shown in Fig. 2B . We considered residues with distances <3.5 Å from ligand atoms. According to Seidler (2013) , Arg249, Asp210, Cis166, His194, Ser165, Thr197, 226 and Tyr333 residues play a significant role in the active enzyme center. These residues participate in the catalytic mechanism of TcGAPDH oxidoreductase activity. We observed that the MP peptide and the TcGAPDH can form three H-bonds: two involving Cis166 of TcGAPDH with Val13 and Asp12 of MP; and another involving Gly245 of TcGAPDH with Lys5 of MP. H-bonds are important in interactions between the ligand and the enzyme, especially with TcGAPDH catalytic residues, such as the Cys166 (Seidler, 2013) . Souza et al. (1998) suggest that the Asp210 residue may be involved in selective inhibition processes. For instance, chalepin inhibits TcGAPDH, but does not inhibit the human GAPDH. The substitution of Asp210 (T. cruzi) by Leu194 (human) can produce less effective polar interactions, decreasing chalepin specificity for the human GAPDH (Pavão et al., 2002) . Thus, the peptide's pose with the highest score obtained from the molecular docking with TcGAPDH suggests the possibility of inhibition of this enzyme. This could be a mechanism for the biological action of the peptide on the parasite.
Regarding all biological processes dependent of GAPDH, its inhibition could be related to ROS induction and mitochondrial disruption, resulting in energetic collapse. This can explain why MP could not cause lyses of membrane (7AAD staining) or induce externalization of PS (AX staining) on epimastigote forms on our assays.
The most important finding of the present study was the activity of MP against the intracellular amastigote form. Amastigotes develop and maintain the infections by T. cruzi and significantly low MP concentrations inhibit amastigote proliferation.
Several chemical reagents with specific biochemical targets are effective inhibitors of parasite attachment and/or invasion. Inhibition of ATP synthesis in T. cruzi with drugs that interfere with glycolysis profoundly affects the level of host cell invasion. The decrease in the invasive capacity results from the severe inhibition of parasite attachment to host cells, reducing amastigote development (Schenkman et al., 1991) .
In conclusion, mastoparan isolated from Polybia paulista wasp venom showed an inhibitory effect on the epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi Y strain. Additionally, we suggest the interaction of MP with TcGAPDH.
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